Establishes the "Hope for Missouri Patients Act"
HB 1206 establishes the “Hope for Missouri Patients Act,” creating a new statutory framework in Chapter 191 for access to individualized investigational treatments. The bill defines an “eligible patient” as someone with a life-threatening or severely debilitating illness who has exhausted FDA-approved treatment options, has physician documentation based on genomic analysis, and gives written informed consent. It also defines “individualized investigational drug, biological product, or device” as a treatment uniquely produced for a single patient based on that patient’s genetic profile, including individualized gene therapies, antisense oligonucleotides, and neoantigen vaccines, while excluding products derived from embryonic stem cells or abortion-related tissues.
The bill allows eligible patients to request such treatments from eligible facilities or manufacturers operating under federal human-subject protections, but it does not require manufacturers to provide them. Facilities or manufacturers may provide the treatment without compensation or may require the patient to pay manufacturing costs. The bill also sets out detailed informed-consent requirements, including warnings about uncertain outcomes, possible worsening of symptoms, potential acceleration of death, hospice implications, and the patient’s responsibility for costs.
HB 1206 limits the bill’s effect on existing law by stating that it does not expand insurance coverage under Chapter 376, does not require government agencies to pay for the treatment, and does not require hospitals or licensed facilities to add services unless they choose to do so. It also protects physicians from discipline or Medicare certification consequences based solely on recommending access to these treatments, prohibits state officials from blocking access, and bars new private causes of action against manufacturers or others who act in good faith and with reasonable care. The bill further provides that an estate is not liable for certain remaining debts if death is proximately caused by the treatment, except for nonexperimental care related to complications.
The overall sentiment in the available record appears supportive or at least favorable, as reflected by the bill’s affirmative framing as a patient-access measure and the absence of recorded committee debate or votes in the provided materials. The bill’s structure suggests an emphasis on patient autonomy and expanded access for terminal or severely ill patients. At the same time, the main points of contention likely concern safety, liability, insurance coverage, and whether the state should be involved in facilitating access to highly individualized experimental treatments that are not required to be offered by manufacturers or paid for by insurers or public programs.
Notable tensions in the bill include the balance between access and risk: it creates a pathway for experimental, patient-specific therapies while explicitly warning that treatment may worsen symptoms or hasten death. Another likely point of debate is the bill’s exclusion of embryonic stem cell- and abortion-derived products, which may reflect a policy or moral limitation not present in all similar access laws. The bill also carefully shields providers and state actors from certain penalties, indicating an effort to prevent regulatory or professional barriers to treatment access.
HB 1206 would add seven new sections to Chapter 191, Missouri law, creating a new patient-access regime for individualized investigational treatments. It would not mandate insurance coverage, public payment, or manufacturer participation, but it would protect participating providers from discipline based solely on recommending access, prohibit state interference with access, and limit liability exposure for compliant actors. It also would affect hospice eligibility, patient cost responsibility, and certain debt obligations tied to treatment-related deaths.
The available record shows no committee transcript or vote history, so there is no documented floor or committee debate to gauge opposition or support. Based on the bill text alone, the measure appears to be framed positively as a patient-centered access bill for people with serious or terminal illnesses. The absence of recorded votes or discussion suggests no clear public controversy is captured in the provided materials, though the policy itself is likely to draw mixed views because it expands access to experimental treatments while limiting coverage and liability.
The main likely points of contention are patient access versus safety and oversight, and whether the state should facilitate individualized experimental therapies that are not FDA-approved. Insurers, government agencies, and hospitals are expressly not required to pay for or provide the treatment, which may concern patient advocates seeking broader coverage. On the other hand, medical and regulatory stakeholders may object to the bill’s limits on disciplinary action, its prohibition on state blocking of access, and its liability protections for manufacturers and providers. The bill’s exclusion of embryonic stem cell- and abortion-derived products may also be a point of ideological disagreement.